Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJCULI)

• Drug Name: M7824 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMJCULI

Molecule-Related Drug Atlas

Drug(s) Targeting Transforming growth factor beta (TGFB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TEW-7197	DM2LBC3	Myeloproliferative neoplasm	2A20	Phase 2	[1]
Bintrafusp alfa	DMB9LRJ	Non-small-cell lung cancer	2C25	Phase 2	[3]
NIS793	DM8LBYT	Pancreatic ductal carcinoma	2C10.0	Phase 2	[1]
LY2382770	DMH3YKJ	Diabetic kidney disease	GB61.Z	Phase 2	[4]
Fresolimumab	DMFZ084	Brain cancer	2A00	Phase 2	[5]
BCA101	DMM0VBU	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
GS-1423	DMS25DL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
ACE-011	DMJ36YH	Anemia	3A00-3A9Z	Phase 1	[8]
AVID200	DMZ39T6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
RG6440	DMVQXFH	Aggressive cancer	2A00-2F9Z	Phase 1	[10]

Drug(s) Targeting Programmed cell death protein 1 (PD-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nivolumab	DMAB9QE	Melanoma	2C30	Approved	[11]
Tislelizumab	DMGVUO5	Hodgkin lymphoma	2B30	Approved	[12]
MK-3475	DMBYNW0	Melanoma	2C30	Approved	[11]
Pembrolizumab	DMFQEA6	Melanoma	2C30	Approved	[2]
Cemiplimab	DMKMJHE	Cutaneous squamous cell carcinoma	2C30	Approved	[13]
Retifanlimab	DMRKTCP	Neuroendocrine cancer	2B72.1	Approved	[14]
Sintilimab	DMGWR0C	Hodgkin lymphoma	2B30	Approved	[15]
Dostarlimab	DM78NWP	Endometrial cancer	2C76	Approved	[16]
Toripalimab	DMSGA6Z	Demodex blepharitis	1G07	Approved in China	[17]
PDR001	DM53J6B	Melanoma	2C30	Phase 3	[18]

Drug(s) Targeting Programmed cell death 1 ligand 1 (PD-L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avelumab	DMSZLJR	Merkel cell carcinoma	2C34	Approved	[19]
Durvalumab	DM4PVDY	Urothelial carcinoma	2C92.0	Approved	[20]
RG-7446	DM69XMQ	Urothelial carcinoma	2C92.0	Approved	[21]
Bavencio	DMU9C8F	Merkel cell carcinoma	2C34	Approved	[22]
Atezolizumab	DMMF8U0	Non-small-cell lung cancer	2C25	Approved	[23]
Sugemalimab	DMH5YQ3	Non-small-cell lung cancer	2C25	Approved in China	[24]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[25]
MEDI4736	DM5X849	Solid tumour/cancer	2A00-2F9Z	Phase 3	[26]
MPDL-3280A	DM9K3LM	Melanoma	2C30	Phase 3	[27]
CS1001	DMSY0NE	Non-small-cell lung cancer	2C25	Phase 3	[28]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	Inhibitor	[1]
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Not Available	[2]
Transforming growth factor beta (TGFB)	TTO3HT7	NOUNIPROTAC	Inhibitor	[1]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [3] Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222.
• [4] A phase I dose-escalation study to a predefined dose of a transforming growth factor-1 monoclonal antibody (TM1) in patients with metastatic cancer. Int J Oncol. 2014 Dec;45(6):2221-31.
• [5] Focal Irradiation and Systemic TGF Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018 Jun 1;24(11):2493-2504.
• [6] ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health.
• [7] Clinical pipeline report, company report or official report of Agenus.
• [8] Clinical pipeline report, company report or official report of Acceleron Pharma (2011).
• [9] TGF signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond Syndrome. J Clin Invest. 2019 Jun 18;129(9):3821-3826.
• [10] Clinical pipeline report, company report or official report of Roche
• [11] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [12] Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364.
• [13] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346.
• [16] Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.
• [17] Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
• [20] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [21] PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
• [22] ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
• [23] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [24] Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
• [25] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [26] National Cancer Institute Drug Dictionary (drug id 740856).
• [27] Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
• [28] GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.